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ABSTRACT
Introduction. Obesity is strongly associated with insulin resistance, known to be related to elevated 
gamma-glutamyltranspeptidase activity (GGTP) and uric acid (UA) level. However, the mechanism of this 
relationship has not yet been clarified. We investigated the relationship of GGTP and UA with anthropometry 
and components of metabolic syndrome in overweight and obese young women. 
Materials and methods. GGTP, UA, fasting glucose, fasting insulin, HOMA and lipids were determined in 
blood samples obtained from overweight (n = 24; BMI = 25–30 kg/m2) and obese (n = 28; BMI > 30 kg/m2) 
women aged 25–40 yrs and age-matched healthy controls (n = 38; BMI < 25 kg/m2). 
Results. GGTP and UA were elevated over the upper reference values only in 19.2% and 11.5% of wom-
en from the study group, but median GGTP and UA were significantly higher in obese and overweight 
women compared to controls. In the whole study group, and in obese women, GGTP activity was more 
associated with WC, WHR and WtHR which was not found for UA. The correlations between GGTP and 
HOMA-IR and fasting insulin were significant for women with excessive body weight and obese women 
only, whereas the correlations between UA and parameters of insulin resistance in the whole study group 
and in obesity did not reach statistical significance. Moreover, we found significant differences in GGTP 
activity between women with and without insulin resistance in both the study group and obese women 
(p < 0.0001; p < 0.01). In the whole study group, and in obese women only, GGTP positively correlated 
with TC, LDL-C, TG, TC/HDL-C ratio, SBP and DBP, whereas in overweight women it only correlated with 
SBP. We also found that women in higher GGTP quartiles had higher concentrations of TC, LDL-C and 
TC/HDL-C ratio (p < 0.03; p < 0.05; p < 0.05 for quartile trend respectively).
Conclusions. GGTP activity and uric acid concentration are higher in overweight and obese women, 
although only GGTP activity seems to be related to anthropometric parameters, insulin resistance and 
atherogenic indices, essential components of metabolic syndrome in young women. GGTP activity may 
be a surrogate marker of insulin resistance and metabolic syndrome.
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Introduction
Overweight and obesity are risk factors for cardio-
vascular and metabolic diseases widely present in the 
modern world. Metabolic syndrome is a cluster of risk 
factors for cardiovascular disease related to insulin 
resistance. It is well known that insulin resistance is 
associated with a fatty liver and that a fatty liver is as-
sociated with elevated gamma-glutamyltranspetidase 
(GGTP) activity [1, 2]. Serum GGTP has been proposed 
as a marker of insulin resistance (IR) and is associated 
with a marked increase in the risk of cardiovascular 
disease. On the other hand in overweight and obesity, 
hyperinsulinaemia secondary to insulin resistance 
may enhance the reabsorption of uric acid and thus 
contribute to the association of hyperuricaemia with 
hypertension. Recent studies in humans suggest that 
elevated uric acid predicts the development of hyper-
insulinaemia and obesity [1, 3–5]. The aim of this study 
was to investigate the association between gamma-glu-
tamyltranspeptidase, uric acid, and the anthropometry 
and components of metabolic syndrome in overweight 
and obese young women.
Material and methods
The study group included 52 young women with 
abnormal body mass aged 20–45 years, recruited from 
patients of the Department of Internal Diseases, E. 
Warminski City Hospital in Bydgoszcz. Of the women, 
24 were overweight (25 kg/m2 ≥ BMI < 30 kg/m2) and 
28 were obese (BMI ≥ 30 kg/m2). The control group 
(BMI < 25 kg/m2) consisted of 38 age-matched women 
(20–45 yrs) recruited on a voluntary basis. All women 
included in the study had not taken any contraceptives, 
anti-inflammatory or other medicines known to affect 
lipid or carbohydrate metabolism. In each subject, body 
weight, height, waist circumference and blood pressure 
were measured and waist to hip ratio (WHR), waist to 
height ratio (WtHR), and BMI were calculated. Insulin 
sensitivity was estimated using the homeostasis model 
assessment of insulin resistance (HOMA-IR). Cutoff 
values for elevated HOMA-IR ≥ 2.75 were accepted 
based on the results of our own study. The diagnosis 
of MS was based on the definitions of the International 
Diabetes Federation (IDF 2005). This was defined as 
central obesity, measured by ethnic-specific waist cir-
cumferences, plus two of the following components: 
hypertriglyceridaemia (TG ≥ 150 mg/dL), HDL-choles-
terol < 50 mg/dL, high blood pressure (≥ 130/85 mm 
Hg) and raised fasting glucose ≥ 100 mg/dL. We used 
the European waist circumference cutoffs (≥ 80 cm in 
women) to define central obesity.
Written informed consent from each participant was 
obtained and the study was approved by the Bioethics 
Committee at Collegium Medicum, Nicolaus Coperni-
cus University.
From all women included in the study, fasting blood 
was drawn in the early morning (7.00–9.00 am). Serum 
was obtained within less than one hour to avoid prote-
olysis and stored deep-frozen (–80°C) in small aliquots 
until assayed, but for no longer than eight months. 
Serum was assayed for gamma-glutamyltrans-
peptidase, uric acid, HDL-C, triglycerides
 
(TG), total 
cholesterol (TC), glucose, (ARCHITECT ci8200, Abbott 
Diagnostics) and insulin (AxSYM, Abbott Diagnostics). 
LDL-C, TG: HDL-C (the index of LDL particle size and 
surrogate for IR) and TC: HDL-C values were calcu-
lated. The clinical cut-points for GGTP and uric acid 
were accepted as > 39 U/L and > 6 mg/dL, reflecting 
elevated as over the respective upper reference val-
ues. The women’s height [cm], weight [kg], waist and 
hip circumferences [cm], and blood pressure [mm Hg] 
were measured using standard methods. Waist circum-
ference was measured in the horizontal plane midway 
between the superior iliac crest and the lower margin 
of the last rib. Hip circumference was taken around 
the pelvis at the point of maximal protrusion of the 
buttocks. Body mass index (BMI) was calculated. Waist 
circumference and waist-to-hip ratio (WHR) served as 
a measure of regional fat distribution. Systolic (SBP) 
and diastolic blood pressures (DBP) were measured 
twice according to the standard procedures, in a seated 
position after at least 5 mins rest, by trained personnel 
using an automatic blood pressure monitor M6 Comfort 
(HEM-7223-E, OMRON, Poland). Three consecutive 
readings were taken, and the average was recorded. 
Insulin resistance was calculated by the homeostasis 
model assessment (HOMA) method, using fasting blood 
glucose and insulin concentrations (HOMA-IR = fasting 
blood glucose mmol/L × fasting insulin µU/ml/22.5).
Statistical methods
All data is presented as mean ± standard deviation 
(Gaussian distribution of results) or median and 25th and 
75th percentile (non-Gaussian distribution). The Student 
T-test and U-Mann-Whitney test were used to compare 
differences. Comparisons of mean values between 
groups were done by ANOVA or Kruskal-Wallis test. 
Pearson’s or Spearman correlation test were used and 
multiple regression analysis was performed. P < 0.05 was 
considered statistically significant. Statistical analysis was 
performed using Statistica 8.0 for Windows (StatSoft).
Results
Mean age was similar in the study group and the 
control group. The baseline characteristics of partici-
pants are shown in Table 1.
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Waist [cm] 108 (100–119) 88 (85–90) 71 (69–74) 0.0001
WHR 0.88 (0.85–0.92) 0.82 (0.80–0.86) 0.76 (0.73–0.80) 0.0001
BMI [kg/m2] 35.3 (32.3–38.4) 27.6 (26.3–28.5) 21.4 (19.6–22.4) 0.0001
WHR — waist to hip ratio; BMI — body mass index 
Data is presented as median (Q1–Q3); statistical significance was taken as p < 0.05
Table 2. Prevalence of elevated values of GGTP and UA 
in the study group
Number of subjects Percentage
GGTP > 39 U/L 10/52 19.2%
UA > 6 mg/dL 6/52 11.5%
GGTP — gamma-glutamyltranspeptidase; UA — uric acid









Obese I Overweight II
GGTP [U/L] 21 (15–34) 14 (10–18) 10 (9–13) 0.00007 0.01
UA [mg/dL] 4.8 (4.4–5.3) 4.4 (3.8–4.8) 3.8 (3.3–4.3) 0.00005 0.005
GGTP — gamma-glutamyltranspeptidase; UA — uric acid; BMI — body mass index 
Data is presented as median (Q1–Q3). Statistical significance was taken as p < 0.05
Elevated activity of GGTP > 39U/L was found in 
only 19.2% of the study group, where eight women 
were obese and only two overweight, while an elevated 
concentration of UA > 6 mg/dl was found in 11.5% (two 
women overweight and four obese) (Tab. 2). None of 
the control women had increased GGTP or UA values.
Median GGTP and UA values were significantly 
higher in obese (21 U/L; 4.8 mg/dL, p < 0.00007; 
p < 0.00005, respectively) and overweight (14 U/L; 
4.4 mg/dL, p < 0.01; p < 0.005, respectively) compared 
to controls (10 U/L and 3.8 mg/dL) (Tab. 3).
Furthermore, we found significant differences 
in GGTP activity and serum uric acid concentration 
between overweight and obese women (p < 0.005; 
p < 0.05) (Fig.1). GGTP activity was also higher in 
women with metabolic syndrome (23 U/L vs 12 U/L; 
p < 0.000001).
In the whole study group, and in obese women, 
GGTP activity was more associated with anthropometric 
predictors of metabolic syndrome risk factors such as 
WC, WHR and WHtR (Tab. 4).
The results of Spearman’s correlations between 
GGTP and UA and parameters of insulin resistance in 
the study group and obese women are presented in 
Table 5. The correlations between GGTP and HOMA-IR 
and fasting insulin were significant for women with 
excessive body weight and in obese women (r = 0.57, 
Figure 1. Gamma-glutamyltranspeptidase (GGTP) and uric acid (UA) in obese (OB) and overweight (OV) women
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Table 4. Association between GGTP activity and UA level with anthropometric parameters
Study group
WC WHR WHtR
GGTP [U/L] r = 0.51 p < 0.000001 r = 0.31 p < 0.001 r =0.50 p < 0.000001
UA [mg/mL] r = 0.20 p < 0.06 ns ns
Obese women
GGTP [U/L] r = 0.31 p < 0.01 r = 0.29 p < 0.02 r = 0.34 p < 0.007
UA [mg/mL] ns ns ns
Overweight women
GGTP [U/L] r = 0.42 p < 0.01 ns ns
UA [mg/mL] ns ns ns
GGTP — gamma-glutamyltranspeptidase; UA — uric acid; WC — waist circumference; WHR — waist to hip ratio; WHtR — waist to height ratio; 
ns — non-significant




GGTP [UL] r = 0.57 p < 0.00002 r = 0.56 p < 0.00003
UA [mg/mL] ns ns
Obese women
HOMA-IR Insulin
GGTP [U/L] r = 0.52 p < 0.004 r = 0.55 p < 0.002
UA [mg/mL] r = 0.33 p < 0.08 r = 0.36 p < 0.06
GGTP — gamma-glutamyltranspeptidase; UA — uric acid; HOMA-IR — homeostasis model assessment of insulin resistance
Statistically significant correlations (p < 0.05)
p < 0.00002; r = 0.56, p < 0.00003 and r = 0.52, 
p < 0.004; r = 0.55, p < 0.002 respectively). The correla-
tions between UA and parameters of insulin resistance 
in the whole study group did not reach statistical signif-
icance, although serum uric acid concentration showed 
a tendency to higher values with insulin resistance in 
obese women. 
Moreover, we found significant differences in the 
activity of GGTP between women with and without in-
sulin resistance in the whole study group (p < 0.0001). 
Similarly, GGTP activity was significantly lower in obese 
women without insulin resistance (p < 0.01) (Tab. 6).
In the whole study group, and in obese women 
only, GGTP positively correlated with TC, LDL-C, TG, 
and atherogenic indices such as TC/HDL, SBP and 
DBP, whereas in overweight women it correlated only 
with SBP. 
Finally, we analysed the relation of lipids with serum 
GGTP in obese women (Tab. 7). Median TC, LDL-C 
concentration and TC/HDL ratios were significantly 
higher in the IV quartile compared to the I quartile and 
we observed also trends to increasing concentrations 
of TG and TG/HDL ratio in relation to GGTP activity. We 
have presented only the results for obese women, but in 
the whole study group these relations were significantly 
higher and stronger.
Discussion
Obese subjects are more likely to develop glucose 
intolerance and diabetes, in part owing to the ability of 
adipose tissue to secrete adipokines, chemokines and 
enzymes into the bloodstream, having a major impact 
on energy homeostasis and progression from obesity 
to atherosclerotic diseases, in particular leading to 
induction of insulin resistance [6]. Obesity is strongly 
associated with IR and metabolic syndrome [1, 7], 
which are known to be associated with an elevated 
gamma-glutamyltranspeptidase (GGTP) level [1, 4, 8]. 
However, the mechanism of the relationship between 
insulin resistance and GGT elevation has not yet been 
clarified. Our observational study confirms the in-
creasing prevalence of elevated GGTP activity (19.2%) 
and UA level (11.5%) in women with excessive body 
mass. According to Botton et al., as early as 8–17 years 
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Table 6. GGTP activity and UA concentration in relation to insulin resistance in the study group and in obese women
Study group with IR
HOMA ≥ 2.75
n = 22




GGTP [U/L] 20 (16–27) 14 (10–20) 0.0001




Obese without IR 
n = 13
HOMA < 2.75 p
GGTP [U/L] 27 (19–46) 16 (12–21) 0.01
UA [mg/mL] 5.1 (4.2–5.8) 4.6 (4.4–5.1) ns
GGTP — gamma-glutamyltranspeptidase; UA — uric acid; HOMA — homeostasis model assessment; ns — non-significant 
Statistically significant correlations (p < 0.05)











Q I vs. Q IV
TC 139 (96–179) 158 (150–165) 222 (172–254) 199 (174–209) 0.03
TG 89 (69–94) 90 (58–100) 121 (109–158) 115 (85–122) 0.09
HDL-C 44 (39–50) 48 (45–54) 47 (42–49) 42 (38–50) ns
LDL-C 76 (45–112) 92 (85–98) 135 (98–169) 121 (112–138) 0.05
TG/HDL-C 1.8 (1.3–2.1) 1.9 (1.1–2.2) 2.8 (2.2–3.6) 2.6 (2.2–3.1) 0.07
TC/HDL-C 3.3 (2.6–4.3) 3.4 (2.8–3.4) 4.7 (4.2–5.1) 4.8 (4.1–5.2) 0.03
GGTP — gamma-glutamyltranspeptidase; UA — uric acid; TC — total cholesterol; TG — triglycerides; HDL-C — high-density lipoprotein-choles-
terol; LDL-C — low-density lipoprotein-cholesterol 
Data is presented as median (Q1-Q3); statistical significance was taken as p < 0.05
old, for the IOTF definition of obesity, GGTP increased 
from 9.4 UI/L in normal weight boys to 11.7 UI/L in 
overweight or obese boys (p = 0.0002). In girls, GGTP 
increased from 8.2 UI/L in normal weight to 9.4 UI/L 
in overweight or obese (p = 0.02) girls [9]. Similarly, 
Pacifico et al. showed that UA concentrations were 
significantly higher in obese children compared to 
controls; moreover, they correlated with the most estab-
lished cardiovascular risk factor (carotid intima-media 
thickness — IMT) [10]. 
We defined two groups of women according to an 
increase in BMI: women with overweight and obese 
women. Our results indicate that median GGTP and 
UA values were significantly higher in obese compared 
to controls. Many prospective studies have shown that 
the activity of GGTP is positively associated with BMI 
[11–13] and central body fat distribution — measured 
as the percentage of body fat adjusted for BMI [14]. 
Therefore, obesity, and particularly abdominal obesity, 
may be associated with plasma concentration of hepatic 
markers even at a weak degree of obesity in adults, as 
in children.
We found significant differences in the activity of 
GGTP between women with and without metabolic syn-
drome (23 U/L vs. 12 U/L; p < 0.000001). Similar results 
were obtained by Lee et al.: activity of GGTP in women 
with MS and without MS was 23 vs. 19 IU/L; p = 0.01, 
respectively [15]. Other population-based studies have 
shown an association between raised GGTP activity and 
metabolic syndrome [2, 16, 17]. 
In epidemiological studies, BMI has been used 
extensively to assess relative weight and obesity status 
and their relation to several health outcomes, including 
hepatic enzymes, whereas anthropometric measures of 
central adiposity, such as waist circumference, WHR, 
and abdominal height, widely used to assess the rela-
tionship between body fat distribution and metabolic and 
cardiovascular diseases, have been scarcely considered 
in their association with liver enzyme activity [1, 15, 18]. 
In recent studies, anthropometric indices of obesity have 
been evaluated as predictors of metabolic syndrome risk 
factors. Waist to height ratio (WHtR) might be an optimal 
anthropometric predictor of metabolic syndrome risk fac-
tors [18, 19]. In our study group, and in obese women, 
only GGTP activity, but not uric acid, was associated 
with WC, WHR and especially with WHtR. 
Gamma-glutamyltranspeptidase is often increased 
in obese subjects. An increase in the activity of liver 
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enzymes has been associated with hepatic steatosis, 
which could be due to the increased effect of insulin in 
the liver. A fatty liver appears to be a cause of hepatic 
insulin resistance. In consequence, this leads to the 
development of systemic insulin resistance and hy-
perinsulinaemia in obesity. Some data indicates that 
hyperuricaemia is indeed an inherent component of 
metabolic syndrome and could also be used as a simple 
marker of insulin resistance [16, 20, 21]. Although in 
our study no significant correlations between UA and 
indicators of insulin resistance were observed, in obese 
or overweight women significant associations between 
GGTP activity and these indicators were found. In line 
with the findings of others [22], our data demonstrated 
that increased GGTP values in women with excessive 
body mass were positively associated with elevations 
of HOMA-IR and fasting insulin. These findings suggest 
the possibility that increased liver enzymes, especially 
GGTP, might reflect metabolic alterations and could 
serve as a clinical indicator for insulin resistance syn-
drome.
Our results agree with other reports relating hyperin-
sulinaemia to raised GGTP activity. Similar observations 
have been described in nondiabetic patients with no 
history of liver disease, where Wallace et al. investigated 
the relationship of liver enzymes to insulin sensitivity and 
intra-abdominal fat. These subjects were divided into 
lean insulin-sensitive (LIS), lean insulin-resistant (LIR), 
and obese insulin-resistant (OIR) groups. In women, 
GGTP levels were also significantly higher in the OIR 
group than in the LIS group, and tended to be higher 
in the LIR than in the LIS group (p = 0.09) [23]. These 
findings raise the possibility that increasing GGTP levels 
(even within the normal range, as in our study) in the 
context of insulin resistance may be an indication for 
lifestyle changes with the aim of weight loss or treatment 
with peroxisome proliferators-activated receptor-gam-
ma agonists [23].
Previous reports in obese children have shown UA 
levels to correlate positively with insulin and HOMA-IR 
after adjusting for age, gender and pubertal stage [10]. 
These findings suggest that in children, as in adults [24], 
hyperuricaemia may be a marker for insulin resistance, 
an underlying condition of metabolic syndrome [10]. 
We were not able to confirm these results, perhaps 
because our study was too small, which is a limitation 
of this study. 
On the other hand, in the Framingham Heart Study, 
Lee et al. examined the relation of GGTP to cardiovas-
cular disease (CVD) risk factors, and prospectively 
determined the risk of new-onset metabolic syndrome, 
incident CVD and death. They indicated that participants 
with GGTP in higher quartiles had higher concentrations 
of TC, LDL-C and TG (p < 0.001 for quartile trend). 
There was no significant association for HDL-C [12]. 
Similarly in our study, TC, LDL-C and TC/HDL-C 
ratio showed significantly higher mean values with 
increasing GGTP quartiles. We observed also trends to 
increasing concentrations of TG and value of TG/HDL 
ratio in relation to the activity of GGTP. Several studies 
have raised the possibility that the newly addressed 
lipid measures might be superior to the traditional ones 
for cardiovascular risk prediction [25]. It is well-known 
that small, dense low-density lipoproteins-cholesterol 
(sdLDL-C) susceptible to posttranslational oxidation 
and glycation are atherogenic. The TG:HDL-C ratio has 
been shown to be useful in assessing the presence of 
small LDL particles in non-diabetic subjects without 
prominent hyperlipidaemia [26]. We observed a trend 
to a higher TG/HDL-C ratio with increasing GGTP 
activity, which could indicate that serum GGTP may 
be associated with an elevated risk of new-onset com-
ponents of metabolic syndrome and cardiovascular 
diseases risk factors. 
Conclusions
We are aware of the limitations of this study, includ-
ing a relatively small group of subjects with overweight 
and obesity; however, we believe that our data could 
have several important clinical implications. Our find-
ings demonstrate that both GGTP activity and uric acid 
concentrations are higher in overweight and obese 
women, although only GGTP seems to be related to 
anthropometric parameters, insulin resistance and 
atherogenic indices, essential components of meta-
bolic syndrome in young women. GGTP activity may 
be a surrogate marker of insulin resistance and meta-
bolic syndrome.
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